Jerusalem, Israel - 4 April, 2013: Brainsway® Ltd. (TASE:BRIN), a company dedicated to providing breakthrough technology for treating a variety of brain disorders, will showcase its novel solutions at major global conferences, including NBS in Leipzig, EPA in Nice, and APA in San Francisco.
Brainsway offers a non-invasive yet highly effective treatment that activates deep brain structures. The efficacy of Brainway's patented technology was recently validated by the FDA, which has granted a wide indication for the treatment of Major Depressive Disorder patients. The technology has approved indications from international institutions for other disorders as well.
Brainsway technology was presented at NBS, the 5th International Conference on Non-invasive Brain Stimulation, on March 19-21 in Leipzig. The objective of the conference was to merge knowledge from basic neurophysiological science with clinical demands in order to further advance the field. Brainsway technology aroused enthusiastic interest at the conference among the research and academic community.
Brainsway will also participate in EPA 2013, the 21st European Congress of Psychiatry, to be held 6-9 April 2013, in Nice, France. The conference will include a multidisciplinary scientific program that will provide a review of important aspects of diagnosis and treatment in psychiatry, and of the latest achievements in this field. The European Psychiatric Association is the largest international association of psychiatrists in Europe, with active members in 75 countries, and includes 33 national psychiatric associations.
Brainsway will also participate in the APA 2013 conference, to be held in May 18-22 in San Francisco by the American Psychiatric Association, the world's largest psychiatric organization. The APA is a medical specialty society representing more than 33,000 psychiatric physicians from the United States and around the world.
Brainsway Ltd. is dedicated to developing and providing advanced technology solutions for treatment of a variety of brain disorders. The unique technology is based on patents registered by the National Institute of Health (NIH) and by the company. Brainsway has an exclusive license from the NIH for the patent and technology.
The company's technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. Brainsway technology is also optimized for research, including an integrated Double-Blind Placebo-Controlled system to aid clinical studies.